lutetium lu 177 vipivotide tetraxetan
lutetium lu 177 vipivotide tetraxetan: 10 clinical trials tracked.
lutetium lu 177 vipivotide tetraxetan evidence translation
What we can confirm
10 tracked trials
What it means
What to watch
Prepared research question
What is verified about lutetium lu 177 vipivotide tetraxetan, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (10)
A Randomized Phase II/III Trial Evaluating Bipolar Androgen Therapy Followed by Darolutamide vs. Standard of Care in Patients With Metastatic Castration Resistant Prostate Cancer
Primary endpoint: Second progression-free survival (PFS2) (Phase II)
A Phase II Study to Validate the Efficacy and Safety of Pluvicto in African American Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Primary endpoint: Radiographic progression-free survival (rPFS)
Radioligand Efficacy Comparison by Initial PSA-Response Outcome in Metastatic CRPC With Lutetium 177Lu PSMA RLT (RECIPROCAL)
Primary endpoint: Overall survival (OS)
Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide Combined With Metastasis-Directed Stereotactic Body Radiotherapy for Oligorecurrent Prostate Adenocarcinoma (ANDROMEDA)
Primary endpoint: Progression free survival (PFS)
A Phase 2 Study of Biomarker-Modulated PSMA Theranostics
Primary endpoint: Prostate-specific antigen (PSA) progression-free survival (PFS)
PREcision DIagnostics in Prostate Cancer Treatment (PREDICT)
Primary endpoint: Objective Response
Vorinostat to Augment Response to 177Lutetium-PSMA-617 in the Treatment of Patients With PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Primary endpoint: Proportion of patients who convert from prostate-specific membrane antigen (PSMA) low to PSMA high
Re-Treatment With 177Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration Resistant Prostate Cancer: A Prospective Phase 2 Trial (RE-LuPSMA STUDY)
Primary endpoint: 12-month overall survival
A Phase 2 Randomized Trial in Patients With Metastatic Castration Resistant Prostate Cancer to Determine the Efficacy of a Flexible Dosing Schedule of Lu-PSMA Treatment up to 12 Cycles Including Potential Treatment Holiday Periods in Comparison to the Standard Fixed Dosing Schedule of Six Cycles Every Six Weeks (FLEX-MRT)
Primary endpoint: 2-year survival rate
Phase I/II Study of CDK4/6 Inhibition With Abemaciclib to Upregulate PSMA Expression Prior to 177Lu-PSMA-617 Treatment in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Chemotherapy
Primary endpoint: Recommended phase 2 dose (Part A)